Class / Patent application number | Description | Number of patent applications / Date published |
424429000 | Contact lens | 56 |
20080241225 | BASIC PROCESSES TO PREPARE ANTIMICROBIAL CONTACT LENSES - This invention relates to antimicrobial lenses containing metals and methods for their production. | 10-02-2008 |
20080260804 | Medical devices having antimicrobial coatings thereon - The present invention provides a medical device, preferably a contact lens, which comprises an antimicrobial coating including at least one layer of polyquat of formula (I) or (II). The antimicrobial coating on the medical device of the invention has a high antimicrobial efficacy against microorganisms including Gram-positive and Gram-negative bacterial, a low toxicity, low coefficient of friction, and increased hydrophilicity while maintaining the desired bulk properties such as oxygen permeability and ion permeability of lens material. Such lenses are useful as extended-wear contact lenses. In addition, the invention provides a method for making a medical device, preferably a contact lens, having an antimicrobial coating thereon. | 10-23-2008 |
20080299179 | Solutions for ophthalmic lenses containing at least one silicone containing component - The present invention relates to a method for reducing the occurrence of superficial punctate staining comprising the step of packaging, storing or contacting an uncoated ophthalmic lens comprising at least one polymeric wetting agent and polymer units derived from at least one silicone containing component in a solution comprising an osmolality of about 220 mOsm/kg or greater. | 12-04-2008 |
20080317819 | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas - A contact lens for delivery of a multiplicity of drugs includes a lens body with a first drug incorporated in a first zonal area of the lens body and a second drug incorporated in a second zonal area of the lens body. The first and second drugs are dissimilar and the first and second zonal areas are spaced apart from one another. | 12-25-2008 |
20090004244 | Iris design as a drug depot for zonal drug delivery by contact lens - A contact lens providing zonal drug delivery includes a lens body having an optical axis and an opaque simulated iris pattern applied to the lens body, about the optical axis, with the pattern including an ophthalmic drug. | 01-01-2009 |
20090004245 | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens - A drug delivery device includes a contact lens along with a drug delivery zone disposed above an applied axis of the lens. A colored layer is disposed over the drug delivery zone in order to mark a color of the drug delivery zone. | 01-01-2009 |
20090060981 | Contact lens based bioactive agent delivery system - A bioactive agent delivery system comprising an optically transparent contact lens having dispersed therein (1) an ophthalmically bioactive agent capable of diffusion through the contact lens and into the post-lens tear film when placed on the eye and (2) associated with the bioactive agent, an ophthalmically compatible polymeric surfactant in an amount sufficient to slow the rate of migration of the bioactive agent through the contact lens. | 03-05-2009 |
20090092655 | NOVEL PREPOLYMERIZABLE SURFACE ACTIVE MONOMERS WITH BOTH FLUORINE-CONTAINING GROUPS AND HYDROPHILIC GROUPS - Provided are surface modified contact lenses formed from one or more fumaric- or itaconic-containing prepolymers having reactive functionality that is complimentary to surface modifying polymers. | 04-09-2009 |
20090142387 | Method For Inhibiting Attachment Of Microorganisms To Biomedical Devices - A method for inhibiting adhesion of bacteria to a surface of a biomedical device is disclosed. The method involves at least (a) incorporating one or more non-functionalized polymers having one or more hydrophilic moieties into an ophthalmic device that is a polymerization product of a comonomer mixture comprising: (i) a major amount of a non-silicone-containing hydrophilic monomer; and (ii) an end-terminal functionalized surfactant; and (b) inserting the ophthalmic device in the eye of a patient, wherein the at least one non-functionalized polymer migrates to the surface of the device in a sustained release manner to inhibit adhesion of bacteria to a surface of the biomedical device. Biomedical devices are also disclosed. | 06-04-2009 |
20090169598 | Treatment of bacterial infections - The invention relates to polypeptides, comprising repeats of peptides derived from apolipoproteins, which exhibit antibacterial activity and to nucleic acids encoding the same. The invention further provides the use of such polypeptides, derivatives, analogues or nucleic acids as medicaments, and also their use in methods of preventing or treating bacterial infection or objects and surfaces. The invention further extends to objects, such as contact lenses, coated with the polypeptides. | 07-02-2009 |
20090191256 | HIGH WATER CONTENT OPHTHALMIC DEVICES - An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device has an evaporative dehydration barrier layer on the surface thereof. A method for the mitigation of evaporative corneal dehydration employing the high water content ophthalmic device is also disclosed. | 07-30-2009 |
20090232871 | Biocompatible polymers and co-polymers, and uses thereof - The invention relates to highly biocompatible or biophilic un-cross-linked or cross-linked polymers comprising one or more side-chain active acrylic amino acids of formula I | 09-17-2009 |
20090238858 | Compositions and Methods for Treating Ophthalmic Diseases - Degradable polymeric compositions containing water-insoluble drugs blended with copolymers of biocompatible diphenol compound monomer units with pendant carboxylic acid groups polymerized with biocompatible diphenol com-pound monomer units with pendant carboxylic acid ester groups and poly(alkylene oxide) blocks, wherein the molar fraction in the copolymer of biocompatible diphenol compound monomer units with pendant carboxylic acid groups and poly(alkylene oxide) blocks relative to the weight percentage of the drug in the composition is effective to provide pseudo-zero order release of the drug from the composition during the sustained-release phase of drug delivery under physiological conditions. Ocular treatment methods and manufacturing methods are also disclosed. | 09-24-2009 |
20090269391 | Drug Delivery System And Methods Of Use - Electrospun fibers are utilized to improve the mechanical characteristics of a contact lens reducing the weight and mechanical strength of the polymers from which the lenses are typically formed. Electrospun fibers are also utilized as a drug delivery system, both through direct use in the eye and by inclusion of the fibers in a contact lens. The fibers are loaded with therapeutic drugs by a variety of methods and processed by coating and cross-linking the fibers. | 10-29-2009 |
20090269392 | Drug Delivery System And Methods Of Use - Electrospun fibers are utilized to improve the mechanical characteristics of a contact lens reducing the weight and mechanical strength of the polymers from which the lenses are typically formed. Electrospun fibers are also utilized as a drug delivery system, both through direct use in the eye and by inclusion of the fibers in a contact lens. The fibers are loaded with therapeutic drugs by a variety of methods and processed by coating and cross-linking the fibers. | 10-29-2009 |
20090324691 | METHODS AND OPHTHALMIC DEVICES USED IN THE TREATMENT OF OCULAR ALLERGIES - Ophthalmic devices containing anti-allergic agents and methods of preparing the same are disclosed herein. | 12-31-2009 |
20100074942 | DEVICE AND METHOD FOR INTRAOCULAR DRUG DELIVERY - Intraocular devices having a drug delivery construct attached thereto, and methods for using the devices for intraocular drug delivery and the treatment and/or prevention of conditions. | 03-25-2010 |
20100092541 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 04-15-2010 |
20100092542 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 04-15-2010 |
20100143444 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection. | 06-10-2010 |
20100158983 | METHOD FOR INCREASING THE PERMEABILITY OF POLYMER FILM - Polymer membranes are disclosed having increased permeability. The process of the present disclosure, for instance, can increase the ion permeability of membranes and/or the gas permeability of membranes. In one embodiment, for instance, a precursor polymer is subjected to energy in an amount sufficient to form damage tracks through the thickness of the polymer. The damage tracks are then oxidized to form free radical groups. The precursor polymer is then hydrolyzed causing ion groups to form that cluster along the damage tracks. In one embodiment, sulfonated tetrafluoroethylene-based copolymer ionomer membranes are formed that have increased conductivity. Other ionomer membranes that may be formed according to the present disclosure include copolymers of a vinyl hydrocarbon and a vinyl carboxylic acid. | 06-24-2010 |
20100178316 | EXTENDED RELEASE OF BIOACTIVE MOLECULES FROM SILICONE HYDROGELS - A dosage form for the administration of a biologically active agent is a silicone hydrogel appliance where the agent is absorbed in a copolymer of at least one siloxane containing monomer and at least one hydrophilic monomer where the appliance is placed in contact with a tissue surface of the patient, such as a contact lens placed in the eye. The appliance can be formed where a copolymer of the siloxane containing and hydrophobic monomers is soaked in a solution of the biologically active agent. The agent can be a non-ionic drug which is absorbed into the appliance from a non-aqueous solution, such as an ethanol solution. | 07-15-2010 |
20100178317 | Lens Care Solutions with Hyaluronic Acid - A method of retaining hyaluronic acid on a surface of a contact lens. The method comprises providing a contact lens care solution comprising;
| 07-15-2010 |
20100203103 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF INFLAMMATION OF OCULAR AND ADNEXAL TISSUES - The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues. | 08-12-2010 |
20100226963 | BI-FUNCTIONAL CO-POLYMER USE FOR OPTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS - The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided. | 09-09-2010 |
20100233242 | ENGINEERED PROTEINS, AND METHODS OF MAKING AND USING - The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes. | 09-16-2010 |
20100239637 | CONTACT LENS DRUG DELIVERY DEVICE - The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner. | 09-23-2010 |
20100285094 | POLYMERIC COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described are methods of making and using such polymeric compositions. | 11-11-2010 |
20100303890 | COPOLYMERS SUITABLE FOR USE IN CORNEAL BANDAGES - Disclosed is a polymer having an affinity for corneal cells such that it can be used as a substrate for the growth of corneal cells, and so is suitable for use in a corneal bandage, especially in the form of a contact lens in which at least the cornea contacting surface is composed of the polymer. The substrate with an affinity for corneal cells is a copolymer comprising units -(A)- and -(B)- in which the units A are derived from aminoalkyl (alkyl)acrylates and the units B are derived from aryloxy, alkoxy or hydroxyalkyl (alkyl)acrylates, and (alkyl)acrylic acids. | 12-02-2010 |
20110104236 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF OCULAR INFLAMMATORY DISORDERS - The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye. | 05-05-2011 |
20110142908 | Ophthalmic Device, and Method of Use Thereof, for Increasing Ocular Boundary Lubrication - The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need. | 06-16-2011 |
20110200661 | ACRYLIC HYDROGELS WITH PENDANT CYCLODEXTRINS, PREPARATION METHOD THEREOF AND USE OF SAME AS RELEASE SYSTEMS AND CONTACT LENS COMPONENTS - The invention relates to acrylic hydrogels with pendant cyclodextrins, the preparation and application thereof as release systems and components of contact lenses. The method for obtaining acrylic hydrogels with pendant cyclodextrins is characterized in that the hydrogels are formed by a polymer lattice obtained by polymerization of mono- and bifunctional acrylic or methacrylic monomers and monomers having glycidyl groups in their structure, to which cyclodextrin units are covalently bound once formed; and the use and applications of the compositions in the preparation of contact lenses with the capacity for incorporating drugs, active substances or demulcents useful in the treatment of pathological or physiological conditions, in the production of topical, transdermal or transmucosal release systems for medicinal products or active substances, and in the preparation of cosmetics. | 08-18-2011 |
20110200662 | Method For The Treatment Of Proliferative Disorders Of The Eye - The present invention relates to method for the treatment or prevention and of proliferative eye diseases including but not limited to: age related macular degeneration associated proliferative retinopathy, proliferative diabetic retinopathy, proliferative vitreoretinopathy, posterior capsular opacification, scaring and fibrosis after glaucoma filtration surgery, uveal melanoma, and retinoblastoma. The method comprises contacting cells in the eye by means of intra-ocular injection or infusion, with a drug that irreversibly inhibits cellular proliferation without causing extensive tissue necrosis or cytotoxicity. In a preferred embodiment the drug is bizelesin. | 08-18-2011 |
20110217355 | CONTACT LENS BASED BIOACTIVE AGENT DELIVERY SYSTEM - A bioactive agent delivery system comprising an optically transparent contact lens having dispersed therein (1) an ophthalmically bioactive agent capable of diffusion through the contact lens and into the post-lens tear film when placed on the eye and (2) associated with the bioactive agent, an ophthalmically compatible polymeric surfactant in an amount sufficient to slow the rate of migration of the bioactive agent through the contact lens. | 09-08-2011 |
20110262519 | METHOD OF IMPROVING LENS ROTATION - Ophthalmic stabilized lenses have improved rotational properties by treating them with a wetting agent after they are at least initially polymerized. | 10-27-2011 |
20120087971 | CONTACT DRUG DELIVERY SYSTEM - A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the intention is a contact lens for delivering a drug through contact with an eye. | 04-12-2012 |
20120164208 | CHITOSAN HYDROGEL DERIVATIVES AS A COATING AGENT WITH BROAD SPECTRUM OF ANTIMICROBIAL ACTIVITIES - The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. | 06-28-2012 |
20120183593 | HYDROGELS USED TO DELIVER MEDICAMENTS TO THE EYE FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASES - This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops. | 07-19-2012 |
20120328687 | FORMULATIONS OF SELECTIVE ALPHA-2 AGONISTS AND METHODS OF USE THEREOF - The invention provides compositions and methods utilizing low concentrations of selective α-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective α-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective α-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness. | 12-27-2012 |
20130011460 | DRUG-CARRYING CONTACT LENS AND METHOD FOR FABRICATING THE SAME - The present invention discloses a drug-carrying contact lens and a method for fabricating the same. The drug-carrying contact lens comprises a contact lens containing at least one amphiphatic hybrid nanocarrier carrying drug molecules. According to the heat or light sensitivity of the drug molecule, the present invention respectively fabricates an encapsulation-type drug-carrying contact lens and a drug-soaking type drug-carrying contact lens. The present invention uses a highly-biocompatible amphiphatic hybrid nanocarriers having superior drug encapsulation capability to wrap the drug molecules. Thereby, the drug molecules are uniformly distributed in the contact lens and can be gradually and locally released to the eye of the user wearing the contact lens. Therefore, the present invention can prevent or cure ocular diseases with the loss and side effects of the drug being reduced. | 01-10-2013 |
20130195952 | EXTENDED OR CONTINUOUS WEAR SILICONE HYDROGEL CONTACT LENSES FOR THE EXTENDED RELEASE OF COMFORT MOLECULES - A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the intention is a contact lens for delivering a drug through contact with an eye. | 08-01-2013 |
20130323295 | MONOMER SYSTEMS WITH DISPERSED SILICONE-BASED ENGINEERED PARTICLES - Provided are compositions containing engineered particles, and methods of making such engineered particles. Polymeric articles, such as contact lenses, prepared from such compositions are also provided. Such engineered particles are dispersible in hydrophilic systems such as monomer systems for preparation of contact lenses. Each of the engineered particles comprises a hydrophobic core and a hydrophilic shell. The hydrophobic core comprises a silicone-based polymer that can have multiple cross-links and/or polymer-polymer entanglement, and the hydrophilic shell is formed from a reactive stabilizer. A residue of the reactive stabilizer or a hydrophilic segment of the reactive stabilizer can form the shell. The particles have an average particle size of less than about 500 nm. | 12-05-2013 |
20140086975 | HYDROGEL FORMULATION FOR DERMAL AND OCULAR DELIVERY - Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed. | 03-27-2014 |
20140099355 | METHOD AND COMPOSITION FOR THE TREATMENT OF MODERATE TO SEVERE KERATOCONJUNCTIVITIS SICCA - The present invention relates to topical ophthalmic compositions for treating or preventing epithelial lesions or ophthalmic disorders, including dry eye or keratoconjunctivitis sicca. | 04-10-2014 |
20140193476 | CHITOSAN HYDROGEL DERIVATIVES AS A COATING AGENT WITH BROAD SPECTRUM OF ANTIMICROBIAL ACTIVITIES - The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. | 07-10-2014 |
20140377327 | EXTENDED RELEASE DRUG-DELIVERY CONTACT LENSES AND METHODS OF MAKING - Contact lenses are described that include particles of polymer fiber mat incorporated into a polymer lens wherein the polymer fiber mat is formed by electrospinning a prepolymer solution. Methods for making the contact lenses with improved oxygen permeability are also described. Methods for making the contact lens with optional therapeutic drug delivery and refractive correction are also described. | 12-25-2014 |
20150104492 | Esculentin 1a Derivatives and Uses Thereof - The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides. | 04-16-2015 |
20160018671 | DRUG DELIVERY FROM CONTACT LENSES WITH A FLUIDIC MODULE - A soft contact lens comprises a module embedded in a soft contact lens material. The module comprises a hydrophobic material having channels formed therein, such that a surface tension of the aqueous solution within the channels inhibits release of therapeutic agent, such as a drug, through the one or more channels. The surface tension of the aqueous solution within the channel can inhibit diffusion of the therapeutic agent through the channel. The channels may comprise a cross-sectional area and optionally a length, such that therapeutic agent is released through the channels when pressure of the eyelid increases. In many embodiments, the contact lens is configured to inhibit release of the therapeutic agent when the contact lens comprises a free floating configuration, for example when stored in a contact lens solution, such that the storage time of the contact lens can be increased substantially. | 01-21-2016 |
20160038636 | CHITOSAN HYDROGEL DERIVATIVES AS A COATING AGENT WITH BROAD SPECTRUM OF ANTIMICROBIAL ACTIVITIES - The present invention relates to water soluble quaternized chitosan derivatives which form hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. Hydrogel is attractive as an antimicrobial coating since its hydrophilicity intrinsically prevents the reversible nonspecific attachment of microbes. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices. This invention describes the formation of novel hydrogels based on quaternized ammonium chitosan derivatives which has been grafted with photocrosslinkable groups, hence providing hydrogels as antimicrobial water shield coating agent. | 02-11-2016 |
20160081921 | OPHTHALMIC DEVICE HAVING THERAPEUTIC AGENT DELIVERY CAPABILITY AND METHOD OF FORMING SAME - The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material. | 03-24-2016 |
20160109725 | CONTACT LENS USE IN THE TREATMENT OF AN OPHTHALMOLOGIC CONDITION - The present disclosure relates to the use of contact lenses for treating one or more ophthalmologic conditions. In some embodiments, the contact lenses may be used to treat presbyopia, induced myopia, computer vision syndrome (CVS), insufficient accommodation, or a condition associated with insufficient accommodation. The contact lens may include a number of regions having different geometries (e.g., curvature, width, diameter) depending on the flattest keratonomy of the cornea to achieve a suitable fit. For example, the contact lens may include an optic zone surrounded by an inner peripheral region and an outer peripheral region surrounding the inner peripheral region, each exhibiting varying degrees of curvature. The fitted contact lens may be selected based on a measured sagittal depth and/or eccentricity of the cornea. When fitted, an appropriate amount of fluid may accumulate between the cornea of the eye and the contact lens. In addition, the lens may exhibit a sufficient amount of apical clearance such that when the wearer blinks, the lens moves no more than 1 mm on the eye. Further, the lens and the eye may be mutually structured such that bubbles greater than 0.5 mm in diameter are prevented from forming between the contact lens and the eye. The contact lens may be used in combination with a suitable bioactive agent providing for enhanced visual correction. | 04-21-2016 |
20160116764 | SYSTEMS AND METHODS FOR PRINTING ON A CONTACT LENS - One embodiment of a contact lens includes a lens body configured to fit directly on the surface of the eye and legible characters positioned on the lens body. Another embodiment of a contact lens comprises a lens body including polymeric material and a lens enhancing material (e.g., ink, silicone material, medicament material, and the like) encapsulated in the polymeric material. The lens enhancing material can be in the form of isolated sections distributed in the surrounding polymeric material. Methods of making contact lenses include forming a first lens layer including a first surface, forming a pattern on the first surface, and forming a second lens layer over the pattern. | 04-28-2016 |
20160151534 | ANTI-MICROBIAL PEPTIDES AND METHODS OF USE THEREOF | 06-02-2016 |
20160158320 | DEVICE AND METHOD FOR THE DELIVERY OF DRUGS FOR THE TREATMENT OF POSTERIOR SEGMENT DISEASE - Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment. | 06-09-2016 |
20160175457 | OCULAR DEVICE | 06-23-2016 |
20160184222 | TIMED RELEASE OF SUBSTANCES TO TREAT OCULAR DISORDERS - A system is disclosed for simple, non-invasive, sustained delivery of ophthalmic substances to the interior of the eye, for the prevention and treatment of eye diseases and conditions. Liposomes and inverted micelles are disclosed as suitable vehicles, and timed release of the substances is effected. Delivery methods include coating of a lens or injection into the eye. | 06-30-2016 |